Evaluation of the Efficacy and Safety of Multiple Subcutaneous Injections of SHR-1918 in Patients With Hyperlipidemia in Poor Control: a Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trials
Latest Information Update: 12 Dec 2024
At a glance
- Drugs SHR-1918 (Primary)
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- Sponsors Beijing Suncadia Pharmaceuticals
- 10 Dec 2024 Status changed from not yet recruiting to active, no longer recruiting.
- 03 Jul 2024 New trial record